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Abstract
Bendamustine (BDM) is an active chemotherapeutic agent approved in the U. S. for treating chronic lymphocytic leukemia
and non-Hodgkin lymphoma. Its chemical structure suggests it may have alkylator and anti-metabolite activities; however
the precise mechanism of action is not well understood. Here we report the concentration-dependent effects of BDM on cell
cycle, DNA damage, checkpoint response and cell death in HeLa cells. Low concentrations of BDM transiently arrested cells
in G2, while a 4-fold higher concentration arrested cells in S phase. DNA damage at 50, but not 200 mM, was efficiently
repaired after 48 h treatment, suggesting a difference in DNA repair efficiency at the two concentrations. Indeed, perturbing
base-excision repair sensitized cells to lower concentrations of BDM. Timelapse studies of the checkpoint response to BDM
showed that inhibiting Chk1 caused both the S- and G2-arrested cells to prematurely enter mitosis. However, whereas the
cells arrested in G2 (low dose BDM) entered mitosis, segregated their chromosomes and divided normally, the S-phase
arrested cells (high dose BDM) exhibited a highly aberrant mitosis, whereby EM images showed highly fragmented
chromosomes. The vast majority of these cells died without ever exiting mitosis. Inhibiting the Chk1-dependent DNA
damage checkpoint accelerated the time of killing by BDM. Our studies suggest that BDM may affect different biological
processes depending on drug concentration. Sensitizing cells to killing by BDM can be achieved by inhibiting base-excision
repair or disrupting the DNA damage checkpoint pathway.
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Introduction
Bendamustine (BDM) represents one of the earliest rationally
designed anticancer drugs that incorporated three functional
groups; a benzimidazole ring, a mechlorethamine group and
a butanoic acid residue. These groups putatively endowed BDM
with both alkylator and anti-metabolite activities. BDM has been
found to be especially effective in hematologic-related cancers
including multiple myeloma, chronic lymphocytic leukemia (CLL)
and indolent B-cell non-Hodgkin lymphoma (NHL) for which the
FDA has approved its use, and multiple myeloma. Importantly,
BDM is highly effective in NHL patients who have failed
conventional alkylator therapies [1], thus supporting the idea that
BDM has different mechanisms of action. Despite the many years
of clinical use of BDM, and demonstration of ability to alkylate
DNA, its precise mechanism of action in cells remains obscure. A
central theme regarding BDM is whether or not it causes
a different cellular insult as compared to standard alkylating
agents (reviewed in [2]). A previous report suggested that the type
of DNA damage induced by BDM was different to that caused by
alkylating agents [3]. For example, the treatment of the non-
Hodgkin lymphoma cell line SU-DHL-1 with BDM led to
a greater increase in the expression of several p53-responsive
genes and DNA damage/repair genes when compared to other
alkylators. The differences in the expression pattern of genes
involved in DNA-damage stress response, apoptosis, cell cycle,
mitosis and DNA replication between BDM and standard
alkylating agents suggested that BDM elicits a different cytotoxic
response that was mediated by a mechanism of action unlike that
of other alkylating agents [3]. Mechanistic studies using human
CLL and mantle cell lymphoma (MCL) cell lines [4] and CLL cells
from patients [5] point to activation of classical apoptosis through
mitochondrial perturbation, Bax induction and activation, release
of cytochrome C and subsequent caspase-3 activation after BDM
treatment. Furthermore, by interrogating CLL and mantle cells
from patients, Roue et al. found no correlation between p53 status
and BDM cytotoxicity [4].
Less well studied is the connection between BDM and cell cycle
progression. Myeloma cells treated with BDM at 10–30 mg/ml
(equivalent to 25–76 mM) arrested in G2 [6], whilst SU-DHL-1
cells treated with BDM at 50 mM resulted in a modest S phase
delay [3]. Whether the different cell cycle responses were due to
idiosyncrasies of the cell lines or due to different concentrations of
drug remains unclear. A major unaddressed question raised by
these studies is whether cell cycle arrest induced by BDM is related
to cell death. Here we set out to characterize the effect of BDM on
cell cycle progression, DNA damage induction and repair, and cell
viability.
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Materials
Bendamustine, propidium iodide, chlorambucil, melphalan and
Chk2 inhibitor II were all purchased from Sigma. The UCN-01
was generously provided by Kyowa Hakko Kirin Co., Ltd. and the
National Cancer Institute, NIH.
Cell lines and culture conditions
All cell lines were originally obtained from the ATCC and
banked at the Fox Chase Cancer Center (FCCC) Cell Culture
facility. Mycoplasma testing was conducted at FCCC prior to
studies. The cell lines HeLa, PANC1, BxPC3, MCF7, MDA-MB-
453 were grown in DMEM supplemented with 10% FBS, 2 mM
glutamine and 1% penicillin, streptomycin and kanamycin (PSK).
OVCAR 5 and 10 cells were grown in RPMI supplemented with
10% FBS, 2 mM glutamine and 1% PSK. U2932 were grown in
RPMI supplemented with 15% FBS, 2 mM glutamine and 1%
PSK. Wildtype and TDG 2/2 MEFs, generated as previously
described [7], were grown in DMEM supplemented with 15%
FBS, 2 mM glutamine, 1% PSK and sodium pyruvate. All cells
were maintained at 37uC, 5% CO2.
Cell viability and apoptosis assays
HeLa cells were seeded into 96 well plates at a density of 1500
cells per well. Cells were treated with BDM (3.125–200 mM) for
24 h. After this time cells were additionally treated either with
UCN-01 (100 nM), Chk2 inhibitor (100 nM) or Go ¨6976 (200 nM)
for an additional 24 h. MTS reagent (CellTiter 96H AQueous
Proliferation Assay, Promega) was added to each well for 4 h
before the absorbance values at 490 nm was read. Experiments
were conducted in triplicate, 3 independent times. Data presented
are the average absorbance values, relative to control 6 SD. For
apoptosis determination, cells seeded and treated as stated above
were stained with Guava Nexin Reagent H (Millipore). Analysis
was conducted using the Easycyte module and Cytosoft SoftwareH
(Millipore). Experiments were conducted 3 independent times,
collecting 2000 events each time. Data shown is the average 6 SD.
Clonogenic assay
HeLa cells were seeded into 6 well plates at a density of 1000
cells per well. Cells were treated for 24 h. Cells were then treated
with and without UCN-01 (100 nM) for 3 h. All drugs were
washed out and cells were left to grow for approximately 10 days.
Cells were fixed using acetic acid:methanol:H2O, (10:10:80), dried
and stained with 0.4% crystal violet in 20% ethanol. Qualitative
images of representative results are presented. For quantification,
colonies were solubilized (1% acetic acid, 30% ethanol) and
absorbance values at 595 nm were read. Values are expressed as
a percentage relative to untreated cells (set to 100% 6 SD).
Experiments were conducted in triplicate, three independent
times. Student’s two-tailed unpaired t test was conducted for
statistics.
Metaphase spreads
Mitotic cells were collected from untreated and BDM at 50 mM
or 200 mM+UCN-01 (100 nM) treatments. Cells for metaphase
spreads were prepared as outlined by [8]. For visualizing, cells
were dropped onto glass slides and stained with DAPI. Mitotic
spreads were viewed and imaged using fluorescence microscopy.
Images shown are representative of those observed.
Electron microscopy
HeLa cells were seeded into 6 cm dishes, synchronized with
thymidine (2 mM) and treated with BDM 50 mM, 200 mM for
18 h. Cells treated with UCN-01 (100 mM) for an additional 9 h
to obtain mitotic cells were fixed with glutaraldehyde solution (3%,
pH 7.4). Samples were prepared for electron microscopy analysis
as previously described [9].
Immunofluorescence
Cells were grown on coverslips, treated with the indicated drugs,
fixed and stained as previously described [10]. To detect DNA
damage induction and repair, antibodies against 53BP1 (Bethyl)
and c-H2AX (Upstate) were used with Alexa Fluor-conjugated
secondary antibodies (Invitrogen). All cells were counter-stained
with DAPI (Molecular Probes). Images were captured using a 406
or 1006 objective mounted on an inverted microscope (Eclipse
TE2000S; Nikon) with a CCD camera (Photometrics Cascade
512F; Roper Scientific) powered by NIS Elements AR (version
3.10) software (Nikon). For quantitative analysis, individual nuclei
were identified using DAPI staining and used to define regions of
interests (ROI), which were then transposed onto other channels.
The sum intensity per nuclei from a minimum of 50 nuclei was
averaged 6 SEM.
EdU incorporation
HeLa cells were treated with nocodazole for 14 h after which
time mitotic cells were collected by mechanical shake-off. Cells
were washed twice with medium and re-plated. BDM and EdU
(10 mM) (Click-iT
TM EdU imaging kit, Invitrogen) were added 2 h
later, when the cells were fully adherent and still in G1, and
incubated for an additional 12 h. Cells were fixed and stained
according to the manufacturer’s protocol. Quantification of EdU
incorporation was performed as described for antibody detection.
Time-lapse video microscopy
HeLa cells stably expressing green fluorescent protein (GFP):his-
tone H2B were seeded into 6 well plates and synchronized in S
phase using thymidine (2 mM). Thymidine was washed out and
11 h later, cells were treated with the indicated drugs for an
additional 18 h. Where appropriate, UCN-01 (100 nM) was
added to wells before being supplemented with HEPES
(25 mM), layered with mineral oil (Sigma) and placed into
a housing chamber which maintained the temperature at 37uC.
Using a Nikon TE2000 microscope (Nikon) controlled by
MetaMorph software (Molecular Devices), bright field and
fluorescent images were captured every 5 minutes for up to
48 h. Individual movies were analyzed manually and a minimum
of 100 cells per treatment scored for the indicated measurements.
For montages, selected frames representing different cell morphol-
ogies are presented.
DNA content analysis via flow cytometry
Following indicated drug treatments, cells were fixed with 70%
ethanol. For analysis, cells were stained with propidium iodide,
RNase A and sodium citrate. Cells were incubated at 37uC for
30 minutes before being analyzed using a Becton Dickinson single
laser three-fluorescence FACScan flow analyzer and Cell Quest
software (Becton Dickinson). DNA content was acquired from
10,000 events and FlowJo software was used to process the data.
Statistical analysis
For statistical analyses, Student’s two-tailed t test was conducted.
Bendamustine Activates Cell Cycle Checkpoints
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e40342Results
BDM displays concentration-dependent effects on cell
cycle response
HeLa cells synchronized in G1 by release from a mitotic
shakeoff were treated with increasing concentrations of BDM and
their cell cycle profiles were assessed 24 h later. Figure 1 shows
that HeLa cells treated with increasing doses of BDM (25–
100 mM) accumulated at a 4 N DNA content indicating a G2/M
delay. In contrast, cells treated with 200 mM BDM were arrested
in S phase. We next confirmed the dose dependent effects of BDM
on the cell cycle in a wide panel of cancer cell lines. Cell lines
derived from pancreatic (PANC1 and BXPC3 cells), breast (MCF-
7 and MDA-MB-435), and ovarian (OVCAR 5 and 10) cancers
responded similarly to HeLa cells (Fig. 1 and Figure S1) in that
50 mM BDM caused a G2 arrest while 200 mM BDM resulted in
an S phase arrest. The concentrations of BDM used here are
consistent with those previously used against a number of epithelial
derived cell lines [11,12], but are generally higher than
concentrations used for leukemic cell lines [12]. To test if this
was a feature of adherent cell lines, we treated the U2932 cells (B
cell lymphoma) with BDM. As seen with the adherent cell lines,
U2932 cells also exhibited a dose dependent cell cycle response,
but at a lower concentration: 10 mM induced a G2 arrest, 50 mM
induced an S phase arrest. The combined data demonstrate that
BDM induces a dose-dependent effect on cell cycle progression in
multiple cell lines.
We measured DNA synthesis to further assess the effects of
BDM on cell cycle progression. HeLa cells synchronized by
mitotic shake-off were treated in G1 with either 50 or 200 mM
BDM in the presence of EdU (10 mM) for 12 h. Cells treated with
50 mM BDM incorporated essentially the same amount of EdU
(98.064.1%) as untreated cells (10064.8%), while cells treated
with 200 mM BDM incorporated only 64.762.6% as compared to
untreated cells (p=1.1610
210). This suggests that 200 mM BDM
reduces the efficiency of replication, consistent with the delay in S
phase progression. Although replication was not grossly affected by
50 mM BDM, the G2 delay may reflect accumulation of
replication errors that did escape the S phase checkpoint.
Bendamustine induces both repairable and irreparable
DNA damage
The cell cycle arrest observed in Figure 1 was likely a result of
BDM-induced DNA damage, activating the DNA damage
checkpoint pathway. We therefore examined phospho-H2AX
(Ser 139), 53BP1 and replication protein A (RPA), three different
DNA damage response proteins, as a direct measure of BDM-
induced DNA damage. We found that BDM induced H2AX foci,
reflecting accumulation at sites of DNA damage (Figure 2A). We
observed a concentration-dependent increase in c-H2AX foci after
24 h treatment. However, after 48 h of treatment with 50 mM
BDM c-H2AX foci was reduced to levels seen in vehicle-treated
cells (Figure 2A). The reduction in H2AX was likely a result of
efficient DNA repair. However, after 48 h treatment with 200 mM
BDM the level of H2AX foci was not reduced. We next confirmed
these results by staining for 53BP1 and RPA. After 24 h treatment
we observed a dose-dependent increase in foci formation, as seen
with H2AX foci. Furthermore, after 48 h with 50 mM BDM levels
of 53BP1 and RPA were reduced to control levels. In contrast, foci
formation persisted after 48 h continuous treatment with 200 mM
BDM.
We next compared the cell cycle profiles of cells treated with
50 mM or 200 mM for 24 h, 48 h continuously or for 24 h with
BDM, followed by 24 h in the absence of drug. Figure S2 shows
the expected cell cycle arrest after treatment with 50 mM BDM for
24 h, but after another 24 h in the presence or absence of BDM,
cells displayed a normal cell cycle profile. This is consistent with
the efficient repair (lack of foci) of DNA damage at 50 mM BDM.
In contrast, the cell cycle arrest induced by 200 mM BDM was
maintained following 48 h continuous treatment, and even 24 h
after BDM was washed out, this did not reverse the arrest. This
finding is consistent with the persistent DNA damage foci at
200 mM BDM.
Since Chk1 is a key regulator of cell cycle response following
cellular exposure to replication stress, we assessed Chk1 phos-
phorylation (Ser-345) as a biochemical readout for cellular
response to BDM. We observed that Chk1 was dose-dependently
phosphorylated by BDM after 24 h treatment (Fig. 2B). Impor-
tantly, after 48 h no signal was observed in cells treated with
50 mM BDM as would be predicted from the IF and cell cycle
data. However, detectable pChk1 was still present in cells treated
with 200 mM BDM, confirming these cells were still checkpoint
arrested. Taken together, these data suggest that DNA damage
induced by 50 mM BDM is efficiently repaired, but at 200 mM
BDM the effects on cell cycle and DNA damage were irreversible.
Involvement of base excision repair in bendamustine-
induced DNA damage
A previous study showed that BDM-induced cell death was
enhanced by an inhibitor of base excision repair (BER) [3]. We
therefore sought to test the involvement of BER in whether BDM-
induced damage. We targeted the essential BER protein apurinic/
apyrimidinic endonuclease (APE1) by using the pharmacological
inhibitor methoxyamine (MX) [13]. We treated HeLa cells with
BDM 50 mM in the presence and absence of methoxyamine and
assessed DNA damage. Untreated or cells treated with BDM
50 mM for 48 h had little c-H2AX foci, as expected (from
figure 2A). However, addition of MX to BDM-treated cells
resulted in the retention of significantly higher levels of c-H2AX
foci than BDM alone or control cells (Fig. 3A). In contrast, using
NU7441, a DNA-PK inhibitor that does not block BER, did not
affect repair of BDM-induced damage.
Thymine DNA Glycosylase (TDG) is a prominent BER enzyme
whose levels are regulated during the cell cycle [14]. For this
reason, we tested its involvement in BDM-induced damage. We
studied an isogenic pair of mouse embryonic fibroblasts (MEFs)
that were either wild type (Tdg
+/+) or with a genetic ablation of the
Tdg gene (Tdg
2/2) [7]. Not only did we observe that Tdg
2/2
MEFs were more sensitive to 10 mM BDM than wild type MEFs,
showing increased c-H2AX staining after 24 h of treatment, but
they also had a reduced ability to repair the DNA damage after
48 h continuous treatment, as compared to wild type MEFs
(Fig. 3B).
Chk1 inhibition accelerates bendamustine-induced cell
death
Since recent pharmacokinetic studies demonstrated that BDM
is rapidly metabolized in patients [15,16], we modified the
clonogenic assay to assess how transient exposure to BDM affects
long term survival. HeLa cells were treated for 24 h with BDM at
50 mM and 200 mM after which time drugs were washed out,
replaced with fresh medium and allowed to recover. As shown in
Figure 4A, colony formation between control cells versus cells
treated with 50 mM BDM was marginally reduced (control
10068.1% versus 87.8611.2%; p,0.05). However, cells treated
with BDM 200 mM showed a dramatic reduction in the number of
colonies formed (control 10068.1% versus 3.561.3%; p,0.0001).
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DNA damage and a sustained cell cycle arrest leads to efficient cell
death. However, given the timescale reflected in the clonogenic
assay after treatment with BDM 200 mM( ,10 days), it is possible
cells may acquire resistance to the drug and escape death. Since
BDM 200 mM induced a sustained cell cycle arrest, we
hypothesized that abrogating the checkpoint would accelerate
killing by BDM. Figure 4B shows that BDM at any concentration
(3.125–200 mM) is not particularly effective at killing HeLa cells
after 48 h of continuous treatment. We next successively treated
cells with BDM (3.125–200 mM) for 24 hours and then added
UCN-01 (100 nM) for another 24 h, before assaying for cell
viability. UCN-01 did not sensitize cells pre-treated with BDM up
to 100 mM to killing. In contrast, viability was significantly
Figure 1. Cell cycle perturbations induced by bendamustine are a widespread phenomenon in cancer cell lines. HeLa, BXPC3, MCF7,
OVCAR 5 and U2932 cells were treated with bendamustine at the indicated concentrations for 24 h. Cell cycle profiles were determined using FACS
analysis.
doi:10.1371/journal.pone.0040342.g001
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01. Similar sensitization was observed with Go ¨6976, another
compound that inhibits Chk1 (data not shown). A pharmacological
inhibitor of Chk2 did not sensitize to killing by any concentration
of BDM in the same range.
Having demonstrated HeLa cell death was increased after BDM
200 mM+UCN-01, but not BDM 50 mM+UCN-01, we next
examined the nature of killing. Cells were stained to discriminate
between necrotic or apoptotic cell death. Notably, only cells
treated with BDM 200 mM+UCN-01 or Go ¨6976 exhibited an
increase in the percentage of apoptotic cells (p,0.01 vs. control)
(Figure 4C and data not shown). It should be noted that UCN-01
alone had no discernable effects on cell viability in any of the
assays performed. Taken together, these findings demonstrate that
forcing cells to overcome the checkpoint induced by 200 mM
BDM, but not 50 mM, BDM causes cells to die more effectively
compared to cells treated with BDM alone.
Overcoming bendamustine-induced checkpoint arrest
via Chk1 inhibition forces cells into premature mitosis
To gain insight as to how inhibition of Chk1 accelerated cell
killing by 200 mM BDM, the fates of individual cells were tracked
by time-lapse microscopy. HeLa cells stably expressing GFP:His-
tone H2B were treated with vehicle, 50 mM or 200 mM of BDM
for 24 h before UCN-01 (100 nM) was added. The time-lapse data
showed that vehicle treated cells entered and progressed normally
through mitosis (average time of mitosis=52.5616.7 minutes)
(Figure 5A, upper panel and Fig. S2). 50 mM BDM caused
a reduction in the percentage of cells entering mitosis over a 24 h
period (Fig S2), consistent with the G2 arrest observed by FACS
analysis. Addition of UCN-01 abrogated the arrest and cells began
to enter mitosis 4 hours later (Figure 5A, middle panel). While
chromosome congression and alignment appeared normal, cells
were nevertheless delayed at metaphase for an average of
89664.7 minutes, as compared to controls that exited
37.5616.7 minutes after metaphase alignment. Upon exiting
mitosis, a fraction of cells exhibited chromosomal aberrations,
Figure 2. Bendamustine induces both repairable and irreparable DNA damage. HeLa cells were treated for 24 or 48 h continuous
treatment with either 50 or 200 mM BDM or 24 h followed by 24 h in the absence of drugs. A. Immunofluorescence analysis was performed to
identify c-H2AX, 53BP1 or RPA foci. Quantification of the average fluorescence per nucleus (nucleus outlined) is shown on the right. For c-H2AX:
*P=8.9610
228 vs. untreated 24 h; ** P=2.1610
231 vs. untreated 24 h; {P=5.2610
245 vs. untreated 48 h. For 53BP1: *P=4.3610
220 vs. untreated
24 h; ** P=4.2610
241 vs. untreated 24 h; {P=2.0610
257 vs. untreated 48 h. For RPA: *P=2.5610
216 vs. untreated 24 h; ** P=2.8610
252 vs.
untreated 24 h; {P=3.3610
258 vs. untreated 48 h. B. Lysates were probed to determine p-Chk1 (Ser345). Total Chk1 and alpha tubulin were used to
determine loading.
doi:10.1371/journal.pone.0040342.g002
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200 mM BDM had a reduced mitotic index, consistent with the
cell cycle data. Inhibition of Chk1 induced mitotic entry but,
unlike at 50 mM BDM, the mitotic figures of these cells were
highly abnormal (Figure 5A, bottom panel). For example the
chromosomes failed to align at the spindle equator, and cells rarely
exited mitosis but instead died without exiting. The few cells that
did exit formed multinucleated cells. Thus, cells forced into mitosis
after 50 mM BDM+Chk1 inhibition progress through mitosis
relatively normally. In contrast, cells forced into mitosis after
200 mM BDM+Chk1 inhibition generate extremely abnormal
mitotic figures, with the majority failing to exit and instead dying
in mitosis (Fig S3).
We next examined the chromosome morphology of cells that
were forced to enter mitosis after treatment with 50 mMo r
200 mM BDM+UCN-01 in greater detail. Metaphase spreads
obtained from control and BDM 50 mM+UCN-01 treated cells
showed no obvious gross structural defects (Figure 5B). In contrast,
the metaphase spreads of BDM 200 mM+UCN-01 samples were
extremely abnormal. Instead of forming discrete chromosomes,
they appeared ‘pulverized’, a phenotype indicative of extensive
chromosome fragmentation [17].
This is consistent with early studies that showed that S phase
cells when fused with mitotic cells underwent premature chromo-
some condensation (PCC) that resulted in a pulverized morphol-
ogy [18]. We therefore used electron microscopy to examine the
ultra-structure of chromosomes after different drug treatments
Figure 3. Involvement of base excision repair in bendamustine-induced DNA damage. A. Immunofluorescence analyses were performed
to detect remaining c-H2AX foci after 48 h continuous treatment with 50 mM BDM in the presence or absence of either methoxyamine (MX) (6 mM)
or the DNA PK inhibitor NU7441 (10 mM). Representative images are shown (left) along with quantitative analysis (right). Average values 6 SD are
shown. *P,0.005 vs. BDM alone. B. DNA damage induction and repair was conducted in assessed MEFs (Tdg
+/+ and Tdg
2/2) after treatment with
BDM at 50 or 200 mM BDM for 24 h or 48 h. Representative images are shown, with nuclei outlined (circles) based on DAPI staining. Average c-H2AX
signal per nucleus 6 SD is quantified (right). 24 h: *p=0.009, **p=2.0610
28, ***p=4.7610
218 vs. untreated WT; {p=0.00015, **p=2.8610
211,
***p=5.2610
210 vs. untreated TDG 2/2. 48 h: ***p=4.1610
210 vs. untreated WT; {p=0.009, **p=1.4610
216, ***p=1.9610
216 vs. untreated TDG
2/2.
doi:10.1371/journal.pone.0040342.g003
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following BDM and Chk1 inhibition. HeLa cells were treated with BDM (50 or 200 mM) for 24 h. Cells were grown for ,10 days before being fixed and
stained. The data presented are the mean absorbance value (O. D. 595 nm) relative to untreated cells, which is set to 100%. Each bar graph represents
the average of 3 individual experiments performed in triplicate 6 SD. {P,0.05 or *P,0.0001 or vs. untreated cells. B. Cell viability assessed by MTS
assay was performed. HeLa cells were treated with BDM (3.125–200 mM) for 24 h. After this time, appropriate wells were co-treated with UCN-01
(100 nM) or Chk2 inhibitor (100 nM) for an additional 24 h. Data presented is the mean of 3 individual experiments performed in triplicate. Cell
viability is expressed as a percentage of untreated cells 6 SD. *P,0.0001 vs. 200 mM BDM alone. C. The percentage of apoptotic cells following
indicated drug treatments was determined using Guava Nexin Reagent
TM. Data presented is the average of 3 individual experiments 6 SD. *P,0.01
vs. untreated viable cells; {P,0.01 vs. untreated apoptotic cells.
doi:10.1371/journal.pone.0040342.g004
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treatment with BDM 50 mM+UCN-01, intact chromosomes were
clearly visualized. However, in mitotic cells generated by the
treatment with BDM 200 mM+UCN-01 chromosomes were
highly fragmented.
Discussion
The studies described here show that BDM can induce an S or
G2 cell cycle arrest depending on its concentration. This effect was
not idiosyncratic of HeLa cells, as it was observed in cell lines
derived from pancreatic, breast and ovarian cancers, at similar
concentrations of BDM. We found that only a ,four-fold
difference (50 and 200 mM for adherent cells, 10 and 50 mM for
lymphoblast) in concentration can change the cell cycle response
from a G2 to an S phase arrest. The maximum concentration of
BDM used in this study, 200 mM, to elicit cell cycle perturbations
in ‘solid’ cancer cell lines are consistent with the IC50 values
obtained in previous studies [12]. While 200 mMi s,8–13 times
higher than clinically achieved [16,19], the lymphoma cell line
U2932 did show the same dose-dependent cell cycle arrest at more
clinically relevant concentrations of BDM; cells treated with
10 mM BDM resulted in a G2 arrest, while 25 mM BDM resulted
in an S phase arrest. These findings suggest that the hematologic
malignancies may be more sensitive than cell lines derived from
Figure 5. Overcoming bendamustine-induced checkpoint arrest via Chk1 inhibition forces cells into premature mitosis. HeLa cells
stably expressing GFP:histone H2B were used for live cell video-microscopy. A. Representative montage of cells progressing through mitosis after
mock treatment (upper panel), BDM at 50 mM (middle) or 200 mM (lower) followed by UCN-01 addition. B. Mitotic cells were fixed for metaphase
spreads and dispersed onto glass slides, allowed to dry and then stained with DAPI. Metaphases were visualized using fluorescence microscopy.
Images shown are representative of metaphases observed under each experimental condition. C. Representative electron micrographs of mitotic
cells generated from untreated, 50 mM or 200 mM BDM+UCN-01 treatments.
doi:10.1371/journal.pone.0040342.g005
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therapeutic value of BDM in the clinic may be associated with the
induction of S phase arrest.
The studies presented here do not resolve the whether BDM
acts as an alkylator, as an anti-metabolite or a combination of the
two. However, we show that BDM at 50 mM and 200 mM has
distinct effects on cell cycle and induction of DNA damage.
Notably, the repair capacity after treatment with 50 mM and
200 mM is distinct: after of 48 h continuous exposure, cells treated
with 50 mM BDM exhibited no discernable markers of DNA
damage, indicating that the damage was efficiently repaired.
Moreover, cells were no longer arrested in G2 but were cycling
normally, further suggesting repair of DNA damage. In contrast,
cells treated with 200 mM BDM for 48 h failed to repair the
damage, as shown by persistent cH2AX foci and sustained cell
cycle arrest. Thus, these data support the notion that DNA
damage induced by 200 mM BDM is repaired much less efficiently
than at 50 mM. Furthermore, these findings are consistent with
observations that not only does BDM induce more DNA double
strand breaks as compared to the alkylating agents cyclophospha-
mide and BCNU, but also the BDM-induced damage is not
repaired as efficiently as these two drugs [11]. Our studies are
unable to distinguish between several distinct, but not necessarily
mutually exclusive models that may account for the generation of
irreparable DNA damage. The most simplistic explanation is that
the amount of damage induced at 200 mM may quantitatively
overwhelm the repair capacity of the cell to an extent that it slows
down DNA replication. Another possibility is that 200 mM BDM
may induce damage that differs qualitatively from that achieved
with 50 mM BDM. A third possibility suggests that 200 mM BDM
may inhibit proteins that are essential for repair. It is possible that
the purine-like ring structure within BDM inhibits key proteins
that require nucleotides for their activity (DNA polymerases,
kinases, helicases). For example, caffeine contains a purine ring
and can inhibit the activity of ATM and ATR, key kinases
involved in double strand break repair [20]. Finally, BDM may be
metabolized differently at the two doses such that only the higher
concentration of BDM (200 mM) is present long enough to cause
irreversible damage to DNA. Further studies are needed to test
these hypotheses.
Our study highlights the potential use of combining BDM with
inhibitors of DNA repair for therapeutic relevance. Using
a combination of cell lines genetically ablated for TDG, as well
as pharmacological inhibition of BER, indicates that at least
a fraction of BDM-induced damage is repaired by BER. However,
we note that repair is attenuated and not completely ablated,
suggesting the involvement of other pathways. It is possible that
mismatch repair that is known to mediate cytotoxicity of alkylating
agents [21] may be involved in the repair of BDM-induced
damage. Nonetheless, previous findings demonstrating that BDM-
induced cytotoxicity was enhanced by co-treating cells with
methoxyamine [3] suggest that combinatorial treatment of BDM
with inhibitors of DNA repair may translate to therapeutic
efficacy.
The difference in DNA damage repair efficiency between the
two concentrations of BDM may help explain our findings on
short term and long term cell viability. Our findings imply that
short term exposure (24–48 h) to BDM at 50 mM induces transient
DNA damage which the cell eventually repairs, leading to no
discernable long-term effects as determined by clonogenic survival
assays. At 200 uM BDM, damage is not repaired and a 95%
reduction in clonogenic survival is observed.
We are currently unsure as to how cells die after treatment with
200 mM BDM but the short term assays provide clues. Using
short-term assays, 48 h continuous exposure to BDM up to
200 mM did not reduce cell viability as compared to control
treatment. Thus, the time and concentration of BDM is sufficient
to activate cell cycle arrest but not to trigger apoptosis. Cell cycle
arrest with 200 mM BDM presented us the opportunity to test the
effect of Chk1 inhibition. Indeed, combining Chk1 inhibitors with
conventional chemotherapy has proved beneficial in pre-clinical
models of pancreatic cancer [22]. We showed that the inhibition of
Chk1, but not Chk2, enhanced killing of BDM-treated HeLa in
a short term assay. The ineffectiveness of Chk2 inhibitors was
previously reported in a multiple myeloma cell line, despite the
fact that BDM treatment activated Chk2 [6]. It is pertinent to note
that sensitization by Chk1 inhibitors only occurred with 200 mM
of BDM, the dose that elicited an S phase arrest. Using
a combination of live-cell video-microscopy, metaphase spreads
and EM, we show that the majority of the cells exhibiting
extremely abnormal mitoses end up dying in mitosis. By killing
cells in mitosis, this combinatorial treatment could reduce the
number of cells that divide, survive, and potentially become
refractory to treatment. Thus, treatment of cancers with BDM in
combination with Chk1 inhibitors may provide a novel therapeu-
tic strategy that warrants further investigation; however, this would
still critically depend on the concentration of BDM that eliciting
an S phase arrest, rather than a G2 arrest in order to kill cancer
cells.
Supporting Information
Figure S1 BDM-induces cell cycle arrest in multiple cell
lines. Indicated cell lines were treated with increasing concen-
tration of BDM for 24 h. Cell cycle profiles were determined using
FACs analysis.
(TIF)
Figure S2 Bendamustine concentration-dependent re-
versible and irreversible cell cycle arrest. Hela cells treated
with 50 or 200 mM BDM for 24, 48 or 24 h in the presence of
drug followed by 24 h in the absence of drug (24 hR24 h wash
out (w/o) were analyzed for cell cycle distribution using FACS
analysis.
(TIF)
Figure S3 Forced entry mitosis results in aberrant
mitosis. A. Quantification from the movie analysis was
performed to measure the of the average time taken (minutes) to
enter and exit mitosis 6 SD (left panel) and the percentage of
mitotic cells that displayed defects including lagging chromosomes
or improper chromosome condensation (right panel). B. Quan-
tification of the percentage of cells that enter mitosis of die in
interphase after drug treatments (left panel), and measuring the
fate of cells that enter mitosis (right panel).
(TIF)
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